Zujiang Yu

机构：Ministry of Education, First Affiliated Hospital of Zhengzhou University · ORCID：0000-0003-0954-5472

发表论文 182 篇 · 总被引 5575 次 · h-index 35

代表论文

• Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial (2025 · Signal Transduction and Targeted Therapy · 被引 20)
• A machine learning model for mortality prediction in patients with severe fever with thrombocytopenia syndrome: a prospective, multicenter cohort study (2025 · Emerging Microbes & Infections · 被引 12)
• Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study (2025 · Hepatology · 被引 10)
• Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study (2025 · Signal Transduction and Targeted Therapy · 被引 10)
• Mechanistic insights into post-translational modifications in hepatic fibrosis: pathogenic roles and therapeutic potentials (2025 · Journal of Translational Medicine · 被引 7)
• Performance and hypothetical clinical impact of an mNGS-based machine learning model for antimicrobial susceptibility prediction of five ESKAPEE bacteria (2025 · Microbiology Spectrum · 被引 5)